Login

Financial Snapshot

Revenue
TTM
$8.409B
Gross Margin
TTM
70.15%
Net Income
TTM
$760.7M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
173.25%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
12.68B
Cash
2026 Q1
P/E
TTM
20.94
Free Cash Flow
TTM
$1.167B

Stock Price

Loading...
Market Cap: $15.928 Billion

About Zimmer Biomet Holdings, Inc

Zimmer Biomet Holdings, Inc (NYSE: ZBH) is a medical device company that designs, manufactures, and sells reconstructive orthopedic implants and related surgical products. Revenue is generated through transactional sales of implants and instruments to hospitals and surgical facilities, with surgeons and healthcare systems as the primary customers. The company operates across knees, hips, shoulders, elbows, and other joints, and competes in the global orthopedic reconstruction market. The 10-K filed 2026-02-20 (accession 000119312526059853) identifies competition, pricing pressures, dependence on new product development, and shifts in product category and regional sales mix as material business risks, consistent with a transactional implant business where product cycles and hospital contracting drive revenue. The filing also flags customer demand changes driven by demographic shifts as a demand driver, pointing to aging populations as a key end-market tailwind. Zimmer Biomet is incorporated in the United States and headquartered in Warsaw, Indiana.

Revenue model
Transactional sales of orthopedic implants, instruments, and related products to hospitals and surgical facilities. Revenue varies by product category mix and regional geography, as noted in the FY2025 10-K (filed 2026-02-20).
Products and services
Reconstructive orthopedic implants for knees, hips, shoulders, elbows, and other joints; surgical instruments and related products. The filing references a product portfolio rationalization plan as of the FY2025 10-K (filed 2026-02-20).
Customers and end markets
Hospitals, surgical facilities, and surgeons. End market demand is tied to orthopedic reconstruction procedures, with demographic changes identified as a driver of customer demand in the FY2025 10-K (filed 2026-02-20).
Value-chain role
Medical device manufacturer and direct seller of orthopedic implants and instruments to healthcare providers.
Geographic exposure
The FY2025 10-K (filed 2026-02-20) references regional sales mix as a factor affecting results, indicating multi-geographic operations, but specific country or segment revenue breakdowns are not supported by the provided excerpts.

Source: SEC 10-K, filed 2026-02-20

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: Abbott Laboratories ABIOMED INC Baxter International Inc Edwards Lifesciences Corp Dexcom Inc HOLOGIC INC IDEXX Laboratories Inc Insulet Corp Resmed Inc Teleflex Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support